Equity Research Analysis: Athira Pharma, Inc. (LONA)
|Blank Capital Research Unit|Spot: $5.78
Price$5.78
Composite Score43.1/100
RatingREDUCE (2★)
Rank#3104 OF 7,333
Market Cap$16M
IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3104
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$16M
Mark J. Litton
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in Phase 3 and ACT-AD clinical trials for the treatment of Alzheimer's disease.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$LONA Athira Pharma, Inc. | 43 | 16 | 23 | 92 | - | - | -192.1% | -171.3% | - | - | - | - | 0.0% | 0.0x | $16M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Athira Pharma, Inc. (LONA) receives a "Reduce" rating with a composite score of 43.1/100. It ranks #3104 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for LONA.
View All RatingsROE proxy -192.1% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 6yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Athira Pharma, Inc. (LONA) as a Reduce with a composite score of 43.1/100 at a current price of $5.78. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Athira Pharma, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 43.1/100 places it at rank #3104 in our full universe.
No Moat
High
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Athira Pharma, Inc. represents a reduce based on multi-factor quantitative performance.
Athira Pharma, Inc. receives a Reduce rating from our analysis, with a composite score of 43.1/100 and 2 out of 5 stars, ranking #3104 out of 7,333 stocks. LONA's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
Athira Pharma, Inc. registers a weak quality score of just 16/100, indicating significant profitability challenges. The company reports a return on equity of -192.1% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
LONA registers a value score of just 23/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.94x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Athira Pharma, Inc.'s investment score of 20/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -171.3% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Athira Pharma, Inc. (LONA) is exhibiting exceptional momentum with a score of 92/100, placing it among the strongest trending stocks in the market. Revenue growth data is not currently available, while a beta of 1.89 reflects its sensitivity to broader market moves. Stocks with momentum scores this high have historically outperformed over the following 3–12 months, suggesting LONA may continue to benefit from strong institutional interest and positive price trends.
Athira Pharma, Inc. registers a low stability score of 16/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.89 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
LONA's short interest factor score of 88/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include high market sensitivity (beta: 1.89), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $16M, Athira Pharma, Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Athira Pharma, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3104 of 7,333 overall (58th percentile). Key comparisons include ROE of -192.1% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While LONA currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (16) would have the largest impact on the composite score.
ROE 10012% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 100% BELOW SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Brings more than 25 years of biopharma business development and corporate strategy expertiseBOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for
New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovationBOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Compa
Here are the biggest calls on Wall Street on Thursday.
Hong Kong, Hong Kong--(Newsfile Corp. - February 5, 2026) - Queen's Road Capital Investment Ltd. (TSX: QRC) (the "Company" or "QRC") announces that on February 5, 2026, it acquired a convertible debenture of ATHA Energy Corp. ("ATHA") in the principal amount of US$25,000,000 (approximately Can. $34,130,000) (the "Debenture"). The Debenture is convertible into 40,152,941 ATHA shares at a price of $0.85 per share. In addition, QRC has been issued 1,552,900 common shares of ATHA in payment of an...